Percutaneous vs. surgical revascularization for patients with unprotected left main stenosis: a meta-analysis of 5-year follow-up randomized controlled trials.
Coronary artery bypass graft
Coronary artery disease
Meta-analysis
Percutaneous coronary intervention
Unprotected left main
Journal
European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796
Informations de publication
Date de publication:
16 09 2021
16 09 2021
Historique:
received:
30
03
2020
revised:
30
04
2020
accepted:
04
05
2020
pubmed:
12
5
2020
medline:
30
3
2022
entrez:
12
5
2020
Statut:
ppublish
Résumé
A 5-year survival of patients with unprotected left main (ULM) stenosis according to the choice of revascularization (percutaneous vs. surgical) remains to be defined. Randomized controlled trials (RCTs) comparing percutaneous coronary intervention (PCI) vs. coronary artery bypass graft (CABG) with a follow-up of at least 5 years were included. All-cause death was the primary endpoint. MACCE [a composite endpoint of all-cause mortality, myocardial infarction (MI), stroke, and repeat revascularization] along with its single components and cardiovascular (CV) death were the secondary ones. Analyses were stratified according to the use of first- vs. last-generation coronary stents. Subgroup comparisons were performed according to SYNTAX score (below or above 33) and to age (using cut-offs of each trial's subgroup analysis). Four RCTs with 4394 patients were identified: 2197 were treated with CABG, 657 with first generation, and 1540 with last-generation stents. At 5-year rates of all-cause death did not differ [odds ratio (OR) 0.93, 95% confidence interval (CI) 0.71-1.21], as those of CV death and stroke. Coronary artery bypass graft reduced rates of MACCE (OR 0.69, 95% CI 0.60-0.79), mainly driven by MI (OR 0.48, 95% CI 0.36-0.65) and revascularization (OR 0.53, 95% CI 0.45-0.64). Benefit of CABG for MACCE was consistent, although with different extent, across values of SYNTAX score (OR 0.76, 95% CI 0.59-0.97 for values < 32 and OR 0.63, 95% CI 0.47-0.84 for values ≥ 33) while was not evident for 'younger' patients (OR 0.83, 95% CI 0.65-1.07 vs. OR 0.65, 95% CI 0.51-0.84 for 'older' patients). For patients with ULM disease followed-up for 5 years, no significant difference was observed in all-cause and cardiovascular death between PCI and CABG. Coronary artery bypass graft reduced risk of MI, revascularization, and MACCE especially in older patients and in those with complex coronary disease and a high SYNTAX score.
Identifiants
pubmed: 32392283
pii: 5835869
doi: 10.1093/ehjqcco/qcaa041
pmc: PMC8686114
doi:
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-485Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL152021
Pays : United States
Informations de copyright
Published on behalf of the European Society of Cardiology.
Références
Heart. 2012 Jun;98(12):914-9
pubmed: 22626899
J Am Heart Assoc. 2019 Dec 17;8(24):e013650
pubmed: 31830873
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Circulation. 2019 Oct 8;140(15):1273-1284
pubmed: 31934782
J Am Coll Cardiol. 2016 Sep 13;68(11):1233-1246
pubmed: 27609687
J Am Coll Cardiol. 2017 Sep 12;70(11):1368-1375
pubmed: 28882235
Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):200-206
pubmed: 31218354
JACC Cardiovasc Interv. 2013 Dec;6(12):1219-30
pubmed: 24355112
Int J Cardiol. 2018 Nov 1;270:107-112
pubmed: 29937300
Lancet. 2018 Mar 10;391(10124):939-948
pubmed: 29478841
Am J Cardiol. 2019 May 15;123(10):1610-1619
pubmed: 30846212
J Am Coll Cardiol. 2011 Sep 27;58(14):1426-32
pubmed: 21939824
Circulation. 2014 Jun 10;129(23):2388-94
pubmed: 24700706
J Am Coll Cardiol. 2015 May 26;65(20):2198-206
pubmed: 25787197
Am Heart J. 2017 Aug;190:54-63
pubmed: 28760214
J Am Coll Cardiol. 2019 Mar 5;73(8):964-976
pubmed: 30819365
Am J Cardiol. 2020 Feb 15;125(4):491-499
pubmed: 31889527
JACC Cardiovasc Interv. 2020 Jan 13;13(1):143-144
pubmed: 31918937
Lancet. 1994 Aug 27;344(8922):563-70
pubmed: 7914958
J Am Heart Assoc. 2019 Apr 16;8(8):e011279
pubmed: 30943827
Lancet. 2020 Jan 18;395(10219):191-199
pubmed: 31879028
J Cardiovasc Med (Hagerstown). 2018 Oct;19(10):554-563
pubmed: 30095584
Eur J Cardiothorac Surg. 2012 Mar;41(3):535-41
pubmed: 22219412
EuroIntervention. 2017 Jul 20;13(4):407-414
pubmed: 28169217
Lancet. 2019 Oct 12;394(10206):1325-1334
pubmed: 31488373
N Engl J Med. 2005 May 26;352(21):2235-7
pubmed: 15917389
Eur Heart J Cardiovasc Pharmacother. 2020 Jan 1;6(1):31-42
pubmed: 31511896
N Engl J Med. 2019 Nov 7;381(19):1820-1830
pubmed: 31562798
Int J Cardiol. 2016 May 15;211:37-42
pubmed: 26970964
JAMA Cardiol. 2017 Oct 1;2(10):1079-1088
pubmed: 28903139